Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 136

Quantum ‘pinball’ state of matter in electrons allows both conducting and insulating properties, physicists discover

Electricity powers our lives, including our cars, phones, computers, and more, through the movement of electrons within a circuit. While we can’t see these electrons, electric currents moving through a conductor flow like water through a pipe to produce electricity.

Certain materials, however, allow that electron flow to “freeze” into crystallized shapes, triggering a transition in the state of matter that the electrons collectively form. This turns the material from a conductor to an insulator, stopping the flow of electrons and providing a unique window into their complex behavior. This phenomenon makes possible new technologies in quantum computing, advanced superconductivity for energy and medical imaging, lighting, and highly precise atomic clocks.

A team of Florida State University-based physicists, including National High Magnetic Field Laboratory Dirac Postdoctoral Fellow Aman Kumar, Associate Professor Hitesh Changlani and Assistant Professor Cyprian Lewandowski, have shown the conditions necessary to stabilize a phase of matter in which electrons exist in a solid crystalline lattice but can “melt” into a , known as a generalized Wigner crystal. Their work was published in npj Quantum Materials.

Physicists observe key evidence of unconventional superconductivity in magic-angle graphene

Superconductors are like the express trains in a metro system. Any electricity that “boards” a superconducting material can zip through it without stopping and losing energy along the way. As such, superconductors are extremely energy efficient, and are used today to power a variety of applications, from MRI machines to particle accelerators.

But these “conventional” superconductors are somewhat limited in terms of uses because they must be brought down to ultra-low temperatures using elaborate cooling systems to keep them in their superconducting state.

If superconductors could work at higher, room-like temperatures, however, they would enable a new world of technologies, from zero-energy-loss power cables and electricity grids, to practical quantum computing systems. And so, scientists at MIT and elsewhere are studying “unconventional” superconductors—materials that exhibit in ways that are different from and potentially more promising than today’s superconductors.

A new patch could help to heal the heart

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help promote healing and regeneration of cardiac tissue.

The new patch is designed to carry several different drugs that can be released at different times, on a pre-programmed schedule. In a study of rats, the researchers showed that this treatment reduced the amount of damaged heart tissue by 50 percent and significantly improved cardiac function.

If approved for use in humans, this type of patch could help heart attack victims recover more of their cardiac function than is now possible, the researchers say.

Common Sweetener Could Damage Critical Brain Barrier, Risking Stroke

Found in everything from protein bars to energy drinks, erythritol has long been considered a safe alternative to sugar.

But research suggests this widely used sweetener may be quietly undermining one of the body’s most crucial protective barriers – with potentially serious consequences for heart health and stroke risk.

A study from the University of Colorado suggests erythritol may damage cells in the blood-brain barrier, the brain’s security system that keeps out harmful substances while letting in nutrients.

MIT researchers invent new human brain model to enable disease research, drug discovery

A new 3D human brain tissue platform developed by MIT researchers is the first to integrate all major brain cell types, including neurons, glial cells, and the vasculature, into a single culture.

Grown from individual donors’ induced pluripotent stem cells, these models — dubbed Multicellular Integrated Brains (miBrains) — replicate key features and functions of human brain tissue, are readily customizable through gene editing, and can be produced in quantities that support large-scale research.

Although each unit is smaller than a dime, miBrains may be worth a great deal to researchers and drug developers who need more complex living lab models to better understand brain biology and treat diseases.

Novel Therapy Developed for Aggressive Melanoma Subtype

Neuroblastoma RAS viral oncogene homolog (NRAS)-mutant melanoma is an aggressive form of skin cancer that develops because of a RAS genetic mutation within the cells. It is a common mutation in melanoma and accounts for 15–20% of melanoma diagnoses. An individual has greater risk of melanoma when exposed to the sun for extended periods of time. Additionally, individuals may have family history of melanoma that would increase their risk. It is important to regularly visit the dermatologist to confirm pigmented or non-pigmented moles are not cancerous. To evaluate each mole doctor’s access the change in shape, color, size, and unusual growth as time progresses.

Melanoma, specifically the NRAS subtype, can grow rapidly and spread to other areas of the body. Symptoms may also include change in nail appearance, eye issues, and mouth sores. While dependent on the stage of cancer, treatment usually includes drugs that target the NRAS pathway. Immunotherapeutic approaches include a checkpoint inhibitor treatment that activates immune cell response. Other forms of treatment include surgery and combination therapy. Scientists are working to learn more about NRAS melanoma and how to develop better treatments. Recent work has shown particular promise of treating NRAS melanoma in the lab and clinic.

A recent article in Cancer Immunology Research, by Dr. Keiran Smalley and others, demonstrated that blocking the RAS pathway in NRAS-mutated melanoma cells limit tumor growth and expansion. Smalley is a Professor and Scientific Director in the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt Cancer Center. His work focuses on understanding melanoma and the immune response after therapeutic treatment. In addition, Smalley is interested in using computational biology and other techniques to not only assess therapeutic benefit but develop novel treatments specific to mutated melanoma cells.

Nobel winner’s lab notches another breakthrough: AI-designed antibodies that hit their targets

Researchers from Nobel Laureate David Baker’s lab and the University of Washington’s Institute for Protein Design (IPD) have used artificial intelligence to design antibodies from scratch — notching another game-changing breakthrough for the scientists and their field of research.

“It was really a grand challenge — a pipe dream,” said Andrew Borst, head of electron microscopy R&D at IPD. Now that they’ve hit the milestone of engineering antibodies that successfully bind to their targets, the research “can go on and it can grow to heights that you can’t imagine right now.”

Borst and his colleagues are publishing their work in the peer-reviewed journal Nature. The development could supercharge the $200 billion antibody drug industry.

/* */